Table 5—

Characteristics of patients who had treatment stopped due to adverse reactions

PatientEthnicitySexAge yrsRegimenSide-effects reportedElevated AST#Elevated ALT#
1White UKFemale3HVomitingYesYes
2White UKFemale15HUrticarial rash
3White UKMale2HClumsyYes
4White UKMale13HBack pain
5White EUFemale26RHNausea, dizziness
6White EUFemale30RHAcute anaphylaxis
7White non-EUFemale31HReaction to H
8White non-EUMale24HMania
9White non-EUMale32RHLimb pain, dizziness
10White non-EUMale31RHHay fever nausea
11White non-EUMale10HDizziness, sickness
12White non-EUMale32RHHepatitis
13White non-EUMale35HSevere itchy skin rash
14White non-EUFemale31HItch, swollen hands
15White non-EUMale30HVomiting
16Asian ISCMale24RHYes
17Asian ISCMale20RHDry mouth
18Asian ISCMale30HVomitingYes
19South-east Asian/ChineseMale32HPain
20South-east Asian/ChineseMale11HItching
21Black AfricanMale29RH
22Black AfricanFemale29RHSleep disturbance
23Black AfricanMale28RHMania
24Black Afro-CaribbeanFemale17HDizziness, nausea
25Black AfricanFemale29HNauseaYes
26Black AfricanFemale33RHItching
27Black AfricanMale22RHYes
28Black AfricanMale31RH
29Black SomaliFemale26RHNausea
30Black SomaliFemale23RHDizziness
31Arab/Middle EasternMale24HIndigestion
32Arab/Middle EasternMale33RHItching
  • AST: aspartate aminotransferase; ALT: alanine transaminase; EU: European Union; ISC: Indian subcontinent; H: isoniazid; RH: rifampicin/isoniazid. #: AST or ALT levels >40 IU·L−1.